Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.

Gastroenterology - 1 Mar 2014

Li Yi-Ping, Ramirez Santseharay, Humes Daryl, Jensen Sanne B, Gottwein Judith M, Bukh Jens

Abstract excerpt

BACKGROUND & AIMS: Hepatitis C virus (HCV) therapy will benefit from the preclinical evaluation of direct-acting antiviral (DAA) agents in infectious culture systems that test the effects on different virus genotypes. We developed HCV recombinants comprising the 5' untranslated region-NS5A (5-5A) from genotypes 1-6 and 2a(JFH1) NS5B-3' untranslated region, and tested the effects of NS3 protease and NS5A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Imidazoles
Share to Oligopeptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proline

Share to Protease Inhibitors

Share to Pyrrolidines

Share to Valine

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 24262279
DOI: 10.1053/j.gastro.2013.11.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.PMID 24262279Read ↗

Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.Semantic proximity Read ↗

Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.Semantic proximity Read ↗

Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.Semantic proximity Read ↗

HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.Semantic proximity Read ↗

Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A InhibitorsSemantic proximity Read ↗

Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.Semantic proximity Read ↗

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4.Semantic proximity Read ↗

Non-genotype-specific role of the hepatitis C virus 5' untranslated region in virus production and in inhibition by interferon.Semantic proximity Read ↗

Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.Semantic proximity Read ↗

Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.Semantic proximity Read ↗

Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.Semantic proximity Read ↗

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.